Kymera Therapeutics KYMR 深 沪
已收盘 08-01 16:00:00 美东时间
42.96
-0.790
-1.81%
华盛通- 最 高43.87
- 今 开43.13
- 成交量 39.34万股
- 最 低 42.68
- 昨 收 43.75
- 总市值 30.14亿
- 52周最高 53.27
- 市盈率 静 --
- 换手率 0.56%
- 52周最低 19.445
- 委 比 71.82%
- 总股本 7015.72万
- 历史最高 91.92
- 量 比 0.69
- 振 幅 2.72%
- 历史最低 9.60
- 每 手 1
- 风险率 9.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gilead sees Q2 EPS hit from IPR&D expenses
Gilead Sciences (NASDAQ:GILD) said that its Q2 financial results will be negatively impacted by $61M in acquired in-process research and development (IPR&D) charges, leading to a ~($0.04) reduction in...
07-12 06:23
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'
Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD.
07-09 20:14
【国盛医药】周专题&周观点：从海外映射寻找下半年创新药新赛道
（转自：国医盛视） 一、医药核心观点 当周（6.30-7.04）回顾与周专题： 当周（6.30-7.04）申万医药指数环比+3.64%...
07-06 20:38
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
Kymera Therapeutics prices $250M stock offering
Kymera Therapeutics (NASDAQ:KYMR) priced its underwritten public offering of $250.8M shares of common stock and pre-funded warrants to purchase shares. Kymera is selling ~5.04M shares and pre-funded...
06-27 14:40
7.5亿美元！吉利德引进口服靶向CDK2分子胶降解剂
（转自：求实药社） 6月25日，吉利德科学和Kymera Therapeutics宣布已达成独家选择权和许可协议，以加快开发及商业化一款靶向CDK2的新型分子胶...
06-27 12:04
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Kymera Therapeutics has priced a $250.8 million underwritten public offering of its common stock and pre-funded warrants. The company is offering 5,044,500 shares at $44.00 per share and 655,500 pre-funded warrants at $43.9999 each. Underwriters have a 30-day option to buy up to an additional 855,000 shares. Proceeds will support Kymera’s pipeline of degrader programs for immunological diseases and general corporate purposes. The offering is expe...
06-27 03:56
Wells Fargo Maintains Overweight on Kymera Therapeutics, Lowers Price Target to $53
Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and lowers the price target from $57 to $53.
06-26 22:19
